44 filings
Page 2 of 3
6-K
ifsj08
26 Jun 19
Current report (foreign)
6:17am
6-K
w28kbc5q5
25 Jun 19
MorphoSys Presents Primary Analysis Data fromL-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019
6:13am
6-K
pakaek5yvyrf2u3w 8xr
24 Jun 19
MorphoSys’s Licensee Janssen AnnouncesTop-line Phase 3
6:13am
6-K
7n4bowiwi69
17 May 19
Current report (foreign)
6:15am
6-K
004pk8j2w8r 5oc8o
9 May 19
First Quarter Interim Statement
6:21am
6-K
62lu7z k3zqe4em
6 May 19
Current report (foreign)
7:36am
6-K
ttcs itpa2f4
25 Apr 19
MorphoSys and Galapagos Announce Initiation of GECKO Phase 2 Study with MOR106 in Atopic Dermatitis Patients
6:20am
6-K
ykl 3p8drbgq
25 Apr 19
MorphoSys Announces that its Licensee Janssen has Expanded
6:14am
6-K
mmcnun c1ybe
18 Apr 19
Current report (foreign)
6:13am
6-K
2u7pmm
12 Apr 19
Current report (foreign)
6:09am
6-K
3nh0hm0z5fa0
8 Apr 19
Current report (foreign)
6:22am
6-K
qbqw3vacw7rxckq
3 Apr 19
Dr. Sarah Fakih joins MorphoSys as Head of Corporate
6:10am
6-K
7pgyr5dz7ud0y
21 Mar 19
MorphoSys andI-Mab Biopharma Announce Initiation of Pivotal
6:17am
6-K
604qtjwertzy0xctbhd
21 Mar 19
Current report (foreign)
6:14am
6-K
dws1wns
15 Mar 19
2018 annual report Morphosys Engineering the Medicines of Tomorrow
6:27am
6-K
3yzj21
15 Mar 19
MorphoSys Presents Results for Fiscal Year 2018
6:23am
6-K
2bb6hdr4u8aq 8t18
11 Mar 19
MorphoSys Provides Updates onL-MIND andB-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL
7:33am
6-K
z41ly m8r
28 Feb 19
Current report (foreign)
8:59am
6-K
c4hs7 6nww02mke
28 Feb 19
Current report (foreign)
6:22am
6-K
uq5fmekfpi7a00lwhxgw
19 Feb 19
Current report (foreign)
9:51am